In several studies, a variety of markers, namely, fibroblast-activation protein, androgen receptors, Ki-67, p53, Ln-γ2, CK17, p75NTR, and PHLDA1, were used to attempt to differentiate morBCC from other lesions, such as desmoplastic trichoepitheliomas (DTEs), microcystic adnexal carcinomas (MACs), and syringomas, with which morBCCs share clinical similarities [5,31,32,41]. This evidence concerns the gene KRT17 and malignant syringoma.